Dr. Hotchkin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1111 NE 99th Ave
Ste 200
Portland, OR 97220Phone+1 503-963-3030Fax+1 503-963-3140
Education & Training
- University of Washington School of Public HealthMS, Epidemiology, Clinical Research, 2007 - 2009
- University of WashingtonFellowship, Pulmonary Disease and Critical Care Medicine, 2009
- Univerity of WashingtonMD, Internal Medicine, Chief Resident, 2005 - 2006
- University of WashingtonResidency, Internal Medicine, 2002 - 2005
- University of WashingtonInternship, Internal Medicine, 2002 - 2003
- University of Washington School of MedicineClass of 2002
Certifications & Licensure
- ID State Medical License 2003 - Present
- OR State Medical License 2009 - 2025
- WA State Medical License 2004 - 2010
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis Start of enrollment: 2007 Aug 01
- Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2011 Jun 01
Publications & Presentations
PubMed
- 1 citationsDefining the pathway to timely diagnosis and treatment of interstitial lung disease: a US Delphi survey.Amy Hajari Case, Scott Beegle, David L Hotchkin, Thomas Kaelin, Hyun Joo Kim
BMJ Open Respiratory Research. 2023-11-24 - 6 citationsClinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry.Hyun J Kim, Laurie D Snyder, Megan L Neely, Anne S Hellkamp, David L Hotchkin
Lung. 2022-02-01 - 21 citationsEffects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis.Lisa Lancaster, Jonathan G. Goldin, Matthias Trampisch, Grace Kim, Jonathan Ilowite
The Open Respiratory Medicine Journal. 2020-09-22
Press Mentions
- Oregon Man’s Survival After Unspeakable Battle with COVID-19 a Testament to Our Healthcare HeroesMay 7th, 2021
- Doc: Alarming Number of Active People in ER with COVIDNovember 18th, 2020
- Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO RegistryOctober 30th, 2020
- Join now to see all
Committees
- Vice Chairman, Clinicians Advisory Committee, ATS 2013 - Present
- Member, Clinicians Advisory Committee, American Thoracic Society 2011 - Present
- Member, Critical Care Crisis Triage Committee, OR Department of Public Health 2011 - 2013
Professional Memberships
- Member
- Member
- Society for Critical Care MedicineMember
External Links
- The Oregon Clinichttp://www.orclinic.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: